Topic:	diabetes (dm)
Title:	GLP-1 Analogues.
Author:	n/a
Source:	IN: Clinical Impact of Incretin-Based Therapies on Type 2 Diabetes Management. Littleton, CO: Medical Education Resources. pp. 11-13.
Availability:	Available from Medical Education Resources. 1500 W. Canal Court, Littleton, CO 80123. Website: www.mer.org. Price: Available free of charge.
Abstract:	New research highlighting the role of incretin hormones in beta cell function, growth, and development shows potential to provide clinical benefit to patients and to expand the current treatment options for managing type 2 diabetes. This chapter on the glucagon-like peptide (GLP-1) analogues is from a monograph on the clinical impact of incretin-based therapies on the management of people with type 2 diabetes. The monograph is based on a continuing education symposium that was held in conjunction with the American Association of Diabetes Educators’ 2005 Annual Meeting. The authors describe the current research on exenatide, an incretin mimetic that has been shown to effectively lower blood glucose levels and improve glycosylated hemoglobin levels (a measure of blood glucose over time). Currently, exenatide is indicated for patients who are failing on metformin, sulfonylureas, or combination therapies. The chapter also mentions liraglutide, previously known as NN2211, which has a longer plasma half-life, enabling once-daily administration. The chapter includes a side bar summarizing the information that patients should know about exenatide injection. 2 figures. 1 table.
Format:	Book Chapter
Language:	English.
Major Keywords:	Diabetes Mellitus. Type 2 Diabetes. Incretin Mimetics. Glucagon. Physiology. Patient Care Management. Hormones. Pancreas. Insulin. Drug Therapy. Exenatide.
Minor Keywords:	Continuing Education. Hyperglycemia. Blood Glucose. Drug Effects. Administration and Dosage. Glycosylated Hemoglobin. Complications.
Publication Number:	DMBK12298.
Return to Search Results